Drug Profile
Riferminogene pecaplasmide
Alternative Names: Cardiovascular gene therapy - sanofi-aventis; Cardiovascular therapeutic protein - sanofi-aventis; DNA-based delivery of Fibroblast Growth Factor 1 (FGF-1) - sanofi-aventis; FGF-1 gene therapy; NV1-FGF; Riferminogen pecaplasmid; Temusi; XRP 0038Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Vical
- Developer Sanofi; sanofi-aventis
- Class Anti-ischaemics; Gene therapies
- Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Peripheral arterial disorders
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Australia (IM)
- 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Belarus (IM)
- 31 Dec 2010 Discontinued - Phase-III for Peripheral arterial disorders in Argentina (IM)